G1 Therapeutics to Participate in the Virtual 2023 B. Riley Securities 3rd Annual Oncology Conference

Rhea-AI Summary

G1 Therapeutics, a commercial-stage oncology company, will present at the virtual 2023 B. Riley Securities 3rd Annual Oncology Conference on January 19, 2023, at 11:30 AM EST. CEO Jack Bailey will be leading the corporate presentation. Investors and interested parties can access the presentation through the company’s Events & Presentations page. G1 Therapeutics focuses on advancing therapies for cancer, with their first product, COSELA® (trilaciclib), currently in use. The company is headquartered in Research Triangle Park, N.C.

News Market Reaction – GTHX

+3.45%

+3.45% Session move

In the trading session that priced this news, GTHX gained 3.45%, reflecting a moderate positive market reaction.

Data tracked by StockTitan Argus on the day of publication.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

RESEARCH TRIANGLE PARK, N.C., Jan. 11, 2023 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, today announced that on January 19th, 2023, at 11:30 AM EST, G1’s Chief Executive Officer Jack Bailey will provide a corporate presentation during the virtual 2023 B. Riley Securities 3^rd Annual Oncology Conference.

The webcast of the event will be accessible on the Events & Presentations page of http://www.g1therapeutics.com.

About G1 Therapeutics
G1 Therapeutics, Inc. is a commercial-stage biopharmaceutical company focused on the development and commercialization of next generation therapies that improve the lives of those affected by cancer, including the Company’s first commercial product, COSELA® (trilaciclib). G1 has a deep clinical pipeline and is executing a tumor-agnostic development plan evaluating trilaciclib in a variety of solid tumors, including colorectal, breast, lung, and bladder cancers. G1 Therapeutics is based in Research Triangle Park, N.C. For additional information, please visit www.g1therapeutics.com and follow us on Twitter @G1Therapeutics.

G1 Therapeutics® and the G1 Therapeutics logo and COSELA® and the COSELA logo are trademarks of G1 Therapeutics, Inc

Contacts:
Will Roberts
Vice President, Investor Relations & Corporate Communications
919-907-1944
wroberts@g1therapeutics.com

FAQ

When will G1 Therapeutics present at the B. Riley Securities Oncology Conference?

G1 Therapeutics will present on January 19, 2023, at 11:30 AM EST.

Who is presenting for G1 Therapeutics at the 2023 B. Riley Securities Conference?

CEO Jack Bailey will be presenting for G1 Therapeutics.

How can I access the G1 Therapeutics conference presentation?

The presentation can be accessed through the G1 Therapeutics Events & Presentations page.

What is the focus of G1 Therapeutics?

G1 Therapeutics develops therapies aimed at improving the lives of cancer patients.

What is COSELA® and its relevance to G1 Therapeutics?

COSELA® (trilaciclib) is G1 Therapeutics' first commercial product used in cancer treatment.